Skip to content

Study of low-responder to Tafluprost ophthalmic solution and Latanoprost ophthalmic solution

Study of low-responder to Tafluprost ophthalmic solution and Latanoprost ophthalmic solution - Study of low-responder to Tafluprost ophthalmic solution and Latanoprost ophthalmic solution

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000002717
Enrollment
100
Registered
2010-01-01
Start date
2010-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma Ocular Hypertension

Interventions

After more than 4weeks of washout period, instill Tafluprost for 8 weeks. Then 4 weeks of second washout period, instill Latanoprost for 8weeks. After more than 4weeks of washout period, instill Latan

Sponsors

Kyoto University Hospital Department of Ophthalmology and visual sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Diagnosed with primary open angle glaucoma or ocular hypertension, and being receiving monotherapy or no-treatment. 2) Intraocular pressure is more than 16 mmHg without treatment or more than 13 mmHg with monotherapy treatment. 3) Over 20 years old on the date of agreement. 4) Both male and female 5) Outpatient care 6) Subjects whose agreement was shown by him/herself.

Exclusion criteria

Exclusion criteria: 1) Having any hypersensitivity to test drugs. 2) Having severe visual field defect (HFA <-15dB) 3) Having absolute scotoma within 5 degrees in the center of the visual field. 4) Having any corneal abnormality or other condition preventing reliable applanation tonometry. 5) Having history of glaucoma surgery. 6) Having history of cataract surgery within 1 year. 7) Having history of refractive surgery. 8) Presence of any external ocular disease, inflammation or infection of the eye and/or eyelids. 9) Subjects need to be treated with corticosteroid during study period. 10) Pregnant subjects and subjects suspected of being pregnant 11) Subjects investigators declare ineligible for any sound medical reason

Design outcomes

Primary

MeasureTime frame
Efficacy: Intraocular Pressure Lowering rate

Secondary

MeasureTime frame
Intraocular Pressure Safety

Countries

Japan

Contacts

Public ContactAtsushi Nonaka

Kyoto University Hospital Department of Ophthalmology and visual sciences

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026